Open Access

Minimally invasive electrochemotherapy procedure for treating nasal duct tumors in dogs using a single needle electrode


Cite

Figure 1

The SiNE. In (A) the prototype, in (B) the scheme of the tip, zoomed from the squared area in A. The electrode consists of a needle isolated surrounded by two parallel plaques at each side.
The SiNE. In (A) the prototype, in (B) the scheme of the tip, zoomed from the squared area in A. The electrode consists of a needle isolated surrounded by two parallel plaques at each side.

Figure 2

Picture of patient 9 during the treatment. The SiNE is inserted in the nasal fossa.
Picture of patient 9 during the treatment. The SiNE is inserted in the nasal fossa.

Figure 3

CT image of patient 11 before and after the treatment. (A) The tumor can be seen occupying the lateral inferior part of the left nasal passage (white arrow). (B) Two months after a single treatment a CR was obtained; as readily observed, the tumor tissue is absent leaving a defect in the nasal wall (white arrow).
CT image of patient 11 before and after the treatment. (A) The tumor can be seen occupying the lateral inferior part of the left nasal passage (white arrow). (B) Two months after a single treatment a CR was obtained; as readily observed, the tumor tissue is absent leaving a defect in the nasal wall (white arrow).

Figure 4

Kaplan-Meier graph of the outcome of dogs with nasal tumors treated using the SiNE with ECT procedure (SiNE group) versus the dogs treated with surgery plus adjuvant chemotherapy (control group).
Kaplan-Meier graph of the outcome of dogs with nasal tumors treated using the SiNE with ECT procedure (SiNE group) versus the dogs treated with surgery plus adjuvant chemotherapy (control group).

Control group patient details

PatientBreedHistologyAdam’s stageCause of death
1PuddleTubulopapillary carcinomaT1Euthanasia due to local progression.
2CrossbreedCarcinomaT2Euthanasia due to local progression.
3Akita InuChondrosarcomaT2Euthanasia due to local progression to central nervous system
4CrossbreedAdenocarcinomaT3Death due to local progression.
5BoxerCarcinomaT4Death due to lung metastasis.
6CrossbreedSquamous cell carcinomaT2Euthanasia due to breathing difficulty.
7CrossbreedCarcinomaT2Euthanasia.
8Labrador RetrieverCarcinomaT3Euthanasia due to uncontrollable pain.
9Fox TerrierSolid carcinomaT2Euthanasia.
10Cocker SpanielAdenocarcinomaT3Euthanasia due to local progression and pain.

SiNE group patient details and treatment outcome

PatientBreedHistologyAdam’s stageResponseClinical Evaluation
1Golden RetrieverAdenocarcinoma grade 3T2PRPartial reduction of clinical signs, with a persistent minimum nasal discharge.
2Miniature PinscherAdenocarcinoma grade 2T2CRComplete resolution of clinical signs.
3Labrador RetrieverSolid carcinoma grade 3T3PRPartial reduction of clinical signs, with persistence of ocular discharge. Death by euthanasia due to distal radius metastasis.
4Old English MastiffAdenocarcinoma grade 2T4PRComplete Resolution of clinical signs.
5CrossbreedSquamous cell carcinomaT2PRPartial reduction of clinical signs with persistence of minimum nasal discharge.
6Labrador RetrieverRound cell sarcomaT3PRComplete resolution of clinical signs.
7CollieSticker sarcomaT1CRComplete resolution of clinical signs.
8Golden RetrieverSquamous cell carcinomaT2PRPartial reduction of clinical signs, sneezing remains every day with occasional nasal discharge. Death by euthanasia based on the owner’s decision.
9Spanish BretonAdenocarcinoma grade 2T4SDNo reduction of clinical signs was observed, sneezing remained every day with continuous nasal discharge and persistent inflammation of the subcutaneous tissue and paranasal sinuses. Death by euthanasia based on poor quality of life.
10Labrador RetrieverSquamous cell carcinomaT2PRPartial reduction of clinical symptoms with occasional sneezing.
11Golden RetrieverFibrosarcomaT2CRComplete resolution of clinical signs.

Adam’s modified staging system

StageTumor characteristics
T1Confined to one nasal passage, paranasal sinus, or frontal sinus with no bony involvement.
T2Any bony involvement, but no evidence of orbital, subcutaneous, or submucosal mass.
T3Involvement of orbit or subcutaneous or submucosal mass.
T4Tumor extension into nasopharynx or cribriform plate.
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Radiology, Internal Medicine, Haematology, Oncology